Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
- Author
- LARSEN, Claus M1 ; FAULENBACH, Mirjam2 ; VAAG, Allan1 3 ; EHSES, Jan A2 ; DONATH, Marc Y2 ; MANDRUP-POULSEN, Thomas1 4 5
[1] Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark
[2] Clinic for Endocrinology and Diabetes, University Hospital Zurich, Zurich, Switzerland
[3] University of Lund, Lund, Sweden
[4] Core Unit for Medical Research Methodology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
[5] Karolinska Institutet, Stockholm, Sweden - Source
Diabetes care. 2009, Vol 32, Num 9, pp 1663-1668, 6 p ; ref : 25 ref
- CODEN
- DICAD2
- ISSN
- 0149-5992
- Scientific domain
- Endocrinology; Nutrition, obesity, metabolic disorders
- Publisher
- American Diabetes Association, Alexandria, VA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Diabète de type 2 Endocrinologie Homme Maladie métabolique Nutrition Traitement Antagoniste récepteur interleukine 1 Endocrinopathie
- Keyword (en)
- Type 2 diabetes Endocrinology Human Metabolic diseases Nutrition Treatment Interleukin 1 receptor antagonist Endocrinopathy
- Keyword (es)
- Diabetes de tipo 2 Endocrinología Hombre Metabolismo patología Nutrición Tratamiento Endocrinopatía
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21E Endocrine pancreas. Apud cells (diseases) / 002B21E01 Diabetes. Impaired glucose tolerance / 002B21E01A Etiopathogenesis. Screening. Investigations. Target tissue resistance
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B30 Public health. Hygiene-occupational medicine / 002B30A Public health. Hygiene / 002B30A11 Miscellaneous
- Discipline
- Endocrinopathies Metabolic diseases Public health. Hygiene-occupational medicine
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 21938979
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2337/dc09-0533 
https://dx.doi.org/10.2337/dc09-0533
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc09-0533\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1663\";s:8:\"\u0000*\u0000epage\";s:4:\"1668\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"LARSEN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Claus M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"FAULENBACH, Mirjam\";i:1;s:11:\"VAAG, Allan\";i:2;s:12:\"EHSES, Jan A\";i:3;s:14:\"DONATH, Marc Y\";i:4;s:23:\"MANDRUP-POULSEN, Thomas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc09-0533\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1663\";s:8:\"\u0000*\u0000epage\";s:4:\"1668\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"LARSEN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Claus M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"FAULENBACH, Mirjam\";i:1;s:11:\"VAAG, Allan\";i:2;s:12:\"EHSES, Jan A\";i:3;s:14:\"DONATH, Marc Y\";i:4;s:23:\"MANDRUP-POULSEN, Thomas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc09-0533\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc09-0533\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1663\";s:8:\"\u0000*\u0000epage\";s:4:\"1668\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"LARSEN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Claus M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"FAULENBACH, Mirjam\";i:1;s:11:\"VAAG, Allan\";i:2;s:12:\"EHSES, Jan A\";i:3;s:14:\"DONATH, Marc Y\";i:4;s:23:\"MANDRUP-POULSEN, Thomas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc09-0533\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1663\";s:8:\"\u0000*\u0000epage\";s:4:\"1668\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"LARSEN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Claus M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"FAULENBACH, Mirjam\";i:1;s:11:\"VAAG, Allan\";i:2;s:12:\"EHSES, Jan A\";i:3;s:14:\"DONATH, Marc Y\";i:4;s:23:\"MANDRUP-POULSEN, Thomas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.2337\/dc09-0533\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"32\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1663\";s:8:\"\u0000*\u0000epage\";s:4:\"1668\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"LARSEN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Claus M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:18:\"FAULENBACH, Mirjam\";i:1;s:11:\"VAAG, Allan\";i:2;s:12:\"EHSES, Jan A\";i:3;s:14:\"DONATH, Marc Y\";i:4;s:23:\"MANDRUP-POULSEN, Thomas\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:83:\"Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
